HURA: SEC Form 10-K filed by TuHURA Biosciences Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for HURA
Across the 11 sessions after earlier HURA headlines, the stock closed higher 6 times and lower 5 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HURA | SPY |
|---|---|---|---|
| Feb 27, 2026 | TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement | +3.1% | -0.5% |
| Feb 25, 2026 | TuHURA Biosciences Announces Participation in Upcoming Investor Conferences | +20.0% | +0.8% |
| Feb 17, 2026 | TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers | -15.0% | +0.2% |
| Feb 12, 2026 | TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | +7.8% | -1.5% |
| Feb 2, 2026 | TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma | -3.0% | +0.5% |
| Dec 15, 2025 | TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone | -6.0% | -0.2% |
Quantisnow market dataNASDAQ
HURA
TuHURA Biosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for HURA
Full HURA profile on Quantisnow Follow HURA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time